The entrepreneurial spirit at UConn has led to the launch of world-changing startups across a variety of industries. Students, faculty, and alumni have grasped the resources available to help turn their ideas into products and services that improve lives. UConn-supported businesses make a lasting impact on Connecticut’s economy and the future of industry. The Technology Incubation Program, for instance, has backed more than 100 startup companies, contributing to the creation of more than 2,000 jobs supported and sustained annually by the University. In addition, more than 600 U.S. patents have been granted based on UConn innovations, with 39 issued last year alone. Read on for a sample of companies with UConn roots, including those developing new medications to treat everything from blindness to gastrointestinal conditions, leading-edge technologies that make life easier, novel devices that cut health care costs, and more.
Are you a UConn student, faculty, or staff member with a startup? Let us know by selecting one of the options below:
Company Man and College Student
By their sophomore year in high school, Ben Grosse ’21 (BUS) and his good friend Bharat Pulgam had amassed an impressive collection of broken earbuds. But their parents were less than impressed at the bills for replacement sets. This sparked an idea for a customizable earbud business and now, Grosse is co-owner and sales director of a $100,000 a year company.
Startup Advances Carbon-Zero Fuels through UConn Partnership
Peter J. Werth
Entrepreneur and philanthropist Peter J. Werth has pledged $22.5 million to UConn to ensure a legacy of entrepreneurship and innovation for students for generations to come. Werth's donation will establish and support the Peter J. Werth Institute for Entrepreneurship and Innovation, which will bring together student and faculty programs fostering entrepreneurship and innovation that potentially have commercial application and can be used to create new companies. In addition to nurturing innovation, the Institute will facilitate entrepreneurship speaker forums and host an entrepreneur-in-residence to instruct students.
Read more on UConn Today.
Connecticut Bioscience Innovation Fund (CBIF)
Small Business Innovation Research (SBIR) Grant
Federal SBIR grants are among the largest sources of early-stage capital for technology commercialization in the United States. Run by various federal agencies like the National Institutes of Health and the National Science Foundation, these grants allow U.S. small businesses with strong commercialization potential to participate in federal research and development. SBIR grants support UConn-related startups including Thetis Pharmaceuticals, Biorasis, and Mobile Sense Technologies.
Biorasis, Inc. is a privately held company committed to developing a wireless, needle-implantable (0.5 x 0.5 x 5 mm) biosensor platform for real time, continuous metabolite monitoring. Based at UConn's Technology Incubation Program, Biorasis is a faculty-owned startup.
Cornovus Pharmaceuticals – UConn Health
Cornovus Pharmaceuticals, Inc. commenced operations in October of 2011. The company is focused on the development of a novel cardioprotective compound, MRS2339, for the treatment of heart failure. MRS2339 is a small molecule that stimulates cardiac myocyte P2X4 receptors, which in turn increases myocyte eNOS and cGMP. The compound has been shown effective in multiple preclinical models of heart failure and currently is progressing through IND enabling studies.
Lipid Genomics – UConn Health
Lipid Genomics is developing its FDA-approved investigational drug targeted at people with variations in the HDL ("good cholesterol") SCARB1 gene. More than 117 million people in the U.S. could benefit from this drug. Lipid Genomics has a potential to generate a very sizable profit as the market size for this therapeutic is $2.8 billion and the market size for their second product, novel immune checkpoint inhibitor lymphocyte activation gene-3 (LAG-3), is $1.4 billion.
Mobile Sense Technologies – Engineering
Mobile Sense™ is building foundational technology enabling off-the-chest wearables for long-term management of cardiac arrhythmias. Mobile Sense replaces invasive and inconvenient cardiac monitoring technology, which requires cables and patches, with a simple armband. Mobile Sense's device is non-adhesive, wireless, and waterproof. Neither surgery nor wires are needed to continuously detect and report dangerous arrhythmias to the doctor. Major device manufacturers are embedding this technology.
Eir Medical Devices – Engineering
Eir Medical Devices developed a device designed to help physicians measure patients’ blood viscosity, a traditionally unused, but promising indicator of cardiac risk, and health for patients on dialysis and certain types of cancers.
Cancer, already the leading cause of death in many high-income countries, is set to become a major cause of morbidity and mortality in the next few decades in every region of the world, irrespective of the level of resource. In the US, approximately 40% of the population will be diagnosed with cancer at some point in their life, that is one person per every US household. Unfortunately, the mortality rate for most cancer types remains greater than 50%. The grand challenge in cancer treatment comes down to choosing the most effective drug for chemotherapy. There are more than 16 million Americans diagnosed with cancer, with 1.6 million being diagnosed every year. More than 70% of them will undergo chemotherapy through this method of trial-and-error and endure painful treatments that may be unnecessary and avoidable.
Encapsulate LLC has developed an automated tumor-on-a-chip system that can grow patient-derived cancer cells ex vivo, and screen them against chemotherapeutic drugs. With this technology, the oncologist can choose the most effective chemotherapy drug prior to treatment on an individualized basis. This will I) reduce the number of unnecessary chemotherapy cycles a patient undergoes, II) lower the costs and duration of treatment, III) increase the success rates of treatment, and IV) improve the patient’s overall quality of life. Our mission is to offer personalized cancer therapy screening in the most accurate, expedited, and cost-effective manner.
Hans Health – UConn Health
Hans Health's platform technology, known as a Genomics Driven Immunoproteomics or GDI, allows rapid identification of personalized tumor mutation profiles that are recognized by cancer patients’ own immune system. This new immune assessment tool has the potential to offer more effective treatment options for some of the most aggressive cancer cases.
Learn more on UConn Today.
Pisces Atlantic is reimagining the essence of how fish are fed on commercial farms. Started in 2018 by founder and proprietor Peter Goggins, the company has developed a proprietary feed formulation designed to end dependence on, and serve as an economical alternative to, environmentally harmful conventional feeds. The feed is made from a blend of sustainable protein sources as well as food waste byproducts. Pisces Atlantic is more than just a company, it is an attempt to reshape the way that seafood is sourced, helping to provide high-quality protein to a growing global population while reducing humanity’s impact on our precious marine ecosystems.
Peter Goggins is a junior pursuing an environmental science major in the College of Agriculture, Health, and Natural Resources. Originally drawn to aquaculture by his interest in fish farming, he chose to start Pisces Atlantic as a means of advancing and improving the industry. Having recently launched with its first commercial customer, Pisces Atlantic is focusing on continued R&D while exploring unique business and manufacturing models.
QR Fertile has developed an at-home testing kit for male fertility. A couple who is having trouble conceiving can get a kit from a fertility specialist, or the pharmacy. The test is simple. The process requires the user to load a semen sample onto our paper-based testing device. The sample then reacts with the reagents in test zones on the paper and produces an array of colors; Finally, the user images the results with his smartphone, and within 10 minutes our mobile app will rapidly return measurements of sperm count, sperm motility, fructose, and pH. In addition to analyzing your fertility, we also track your lifestyle, looking for clues of any detrimental habits that are affecting your reproductive health. We then give you smart insights to help you better understand how your life is affecting your health, and when necessary, we suggest lifestyle tweaks to guide your path. Last but not least, we connect users to doctors through our state-of-the-art telemedicine platform. This way you can get lifestyle planning, prescriptions and more from a real physician.
Voxion, Inc. is a voice technology company, making interactive content for Alexa and the Google Assistant. Voxion connects your phone to your smart speaker to provide visually engaging party games that you can share with friends and family.
Learn more at voxion.us.
YouComm – Engineering
YouComm is a tablet-based platform that allows a patient to choose their problem or need from a list or write a custom message that will be sent via text message directly to their caregiver. YouComm incorporates head-movement tracking and voice recognition technology for patients who are immobile.
Read more on UConn Today.
Avitus™ Orthopaedics, Inc. was established in 2011 with the mission of developing new orthopaedic technologies that improve clinical outcomes while decreasing health care costs. The company is developing a novel surgical device that will enable surgeons to use autologous bone graft material to improve the lives of patients. Avitus is currently looking to close their Series A round.
Dashride is the leading provider of mobile dispatching software for transportation companies, supporting nearly 500 transportation companies in most major U.S. cities, the United Kingdom, Singapore, and Australia. The comprehensive software grew out of Sobrio, a sober rides company that won UConn’s Business Plan Competition and the School of Business’ first Innovation Quest competition when its founders were students.
Learn more on UConn Today.
Enviro Power is a Connecticut-based company bringing to market heating equipment that provides high-efficiency heat and generates low-cost electricity. Called SmartWatt, it gives building owners and homeowners the ability to lower both their heating and electricity costs with something every home and building needs anyway – heating equipment.
Torigen Pharmaceuticals, Inc. has developed a treatment that can work for multiple tumor indications, treating more than 2 million companion animals diagnosed with cancer each year. Its product, VetiVax, is a novel, personalized immunotherapy that uses the animals’ own tumor cells to fight cancer. When combined with an innovative bulking agent, MIMTM (Matrix Immune Modulator), an overall reduction in tumor size and inhibition of metastasis have been noted. The treatment has been proven safe in a Phase I trial.
LambdaVision, Inc. (LVI) is developing a high-resolution, protein-based retinal implant to restore vision to the millions of patients blinded by retinal degenerative diseases, including retinitis pigmentosa (RP) and age-related macular degeneration (AMD). Based on a UConn chemistry discovery, the patent-protected retinal implant technology developed by LambdaVision uses the light-activated protein, bacteriorhodopsin, to replace the function of the damaged photoreceptor cells. The flexible, subretinal implant is powered by incident light and does not require any external power supplies or bulky hardware on or outside the eye, and offers the potential for far greater resolution than competing electrode-based technologies. LambdaVision, whose CEO is a UConn alumna, is currently at the pre-seed stage, but is looking for seed money to support further preclinical development.
Thetis Pharmaceuticals LLC is developing novel drugs to treat inflammation-related gastrointestinal diseases with high unmet medical needs. The lead candidate, TP-252, is rapidly advancing through pre-clinical evaluations with the goal of beginning clinical FDA studies in 2018. Thetis aims to partner with a large pharmaceutical company to bring TP-252 to market by 2023.